Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Humans

Unmet human pain and wound care need

At present there is no commercially available product for humans that can be sprayed onto wounds in emergency situations to promptly alleviate pain, minimise bleeding, provide antisepsis and create a protective barrier.

Demonstrated commercial success

We are now developing our technology to prevent pain and minimise suffering associated with wounds in humans.

We have demonstrated the commercial success of our lead product, Tri-Solfen®, for animals. Data from these animal studies suggest that a sterile formulation, Medi-Solfen®, may be equally safe and effective for use on humans. A multi-function topical formulation,  Medi-Solfen® has been developed from our platform technology, that has the potential to revolutionise the acute management of open wounds in humans, to alleviate suffering, to reduce the risk of blood loss and infection and improve recovery, in the same manner that Tri-Solfen® has done in animals.

Phase 2 human studies of Medi-Solfen®, are scheduled to commence shortly, as we progress the technology through the human regulatory approval process.

Chronic wound care

Medi-Solfen® has the potential to treat chronic wounds such as venous leg ulcers, diabetic foot ulcers and pressure ulcers

Chronic wounds affect millions of people globally, which is expected to rise significantly due to the increasing proportion of elderly patients living longer. There are three main types of chronic wounds; venous leg ulcers, diabetic foot ulcers and pressure ulcers. We are initially focused on the development of our technology for the treatment of venous leg ulcers, which represent 80% of all chronic ulcers.

Cleansing chronic wounds of local barriers, such as dead tissue, is known as debridement and is an essential process to facilitate efficient healing. It has been shown that faster and more complete healing is achieved with more frequent debridement.

However, debridement of chronic wounds is not well tolerated and patients will often ask clinicians to stop before the procedure is completed, or avoid the procedure, because of the pain and discomfort. This pain also extends beyond completion of the procedure.

Patients with venous leg ulcers report pain to be the worst aspect of having an ulcer. Chronic pain is highly complex, may extend over months or years, and has enormous implications for a patient’s quality of life, causing decreased activities of daily living, sleep disturbance, reduced mobility and social withdrawal.

It has been shown that when patients with venous leg ulcers feel an ease or absence of pain they interpret it as a positive sign of wound healing, which can make them feel hopeful and optimistic.

Supported by our trial data from our approved animal product (Tri-Solfen®), we have initiated the regulatory approval process, for Medi-Solfen®, for a number of indications in humans.

1 in 500 people suffering

Venous leg ulcers are estimated to affect around 1 in 500 people in the UK, although they become much more common with age. It's estimated that around 1 in 50 people over the age of 80 has one.

Up to 10% of diabetics

422 million adults have diabetes. Up to 10% of them will develop a diabetic foot ulcer at some point.

Supporting studies and references

Cost of wound care

Economic pressure and challenges to prove efficacy in a world where populations and social burden is growing, means healthcare payors are increasingly asking for financial justification for treatments. Medi-Solfen® aims to reduce both the financial and personal costs relating to chronic wound care. The following scientific publications and reference materials support our efforts towards the cost of wound care:

The costs of skin breakdown and ulceration in the UK

Read more

SkinBreakdown

Chronic wounds represent a significant burden in the UK – to patients and to the healthcare system. With proper diagnosis and treatment, much of this burden is avoidable. The purpose of this paper is to provide an estimate of the annual cost of chronic wounds to the NHS. There are around 200,000 individuals in the UK at any time with a chronic wound – many more new wounds develop annually. The cost to the NHS of caring for these patients is conservatively estimated at £2.3bn to £3.1bn per year (at 2005/06 prices) – around 3% of total estimated 2005/06 expenditure on health (£89.4bn).

See full PDF

Close


Making the case for cost-effective wound management – an expert working group review

Read more

International Consensus

Clinicians who treat patients with wounds need access to the resources that will enable them to deliver the best and most appropriate treatments. With economic constraints on healthcare budgets, in addition to challenges to prove efficacy, budget holders and payors are increasingly asking for financial justification for the provision of treatment. Clinicians therefore need to know how to provide such justification to ensure continued provision of appropriate wound management services, including the implementation of service improvements and new technologies.

See full PDF

Close


Venous leg ulcer management in clinical practice in the UK: costs and outcomes

Read more

International Wound Journal

The aim of this study was to estimate the patterns of care and annual levels of health care resource use attributable to managing venous leg ulcers (VLUs) in clinical practice by the UK’s National Health Service (NHS) and the associated costs of patient management. This was a retrospective cohort analysis of the records of 505 patients in The Health Improvement Network (THIN) Database. Patients’ characteristics, wound-related health outcomes and health care resource use were quantified, and the total NHS cost of patient management was estimated at 2015/2016 prices. Overall, 53% of all VLUs healed within 12 months, and the mean time to healing was 3⋅0months. 13% of patients were never prescribed any recognised compression system, and 78% of their wounds healed. Of the 87% who were prescribed a recognised compression system, 52% of wounds healed. Patients were predominantly managed in the community by nurses with minimal clinical involvement of specialist clinicians. Up to 30% of all the VLUs may have been clinically infected at the time of presentation, and only 22% of patients had an ankle brachial pressure index documented in their records. The mean NHS cost of wound care over 12months was an estimated £7,600 per VLU. However, the cost of managing an unhealed VLU was 4.5 times more than that of managing a healed VLU (£3,000 per healed VLU and £13,500 per unhealed VLU). This study provides important insights into a number of aspects of VLU management in clinical practice that have been difficult to ascertain from other studies and provides the best estimate available of NHS resource use and costs with which to inform policy and budgetary decisions.

See full PDF

Close


Health economic burden that wounds impose on the National Health Service in the UK

Read more

BMJ Open

This study estimated the health outcomes, resource implications and associated costs attributable to managing wounds in 2012/2013 using real world evidence obtained from The Health Improvement Network (THIN) database (a nationally representative database of clinical practice among >11 million patients registered with general practitioners in the UK).

See full PDF

Close


Pain and wound healing the direct correlation

Patients living with a chronic wound are often subjected to dressing changes, which can exacerbate their pain and dressing removal is considered to be the most painful aspect of the dressing procedure. This is particularly problematic where a dressing has stuck to the wound or removal of a dressing has torn the skin. Pain at dressing changes can also be evoked by the debridement of slough and necrotic tissue, the application of antiseptics and the use of wound cleansing procedures.

Optimising wellbeing in people living with a wound: an expert working group review

Read more

International consensus

People ‘at risk’ of, or those living with a wound face major changes in their everyday lives and
need to integrate a number of treatment-related procedures that may be difficult to adopt long
term and conflict with existing lifestyles, priorities and behaviours

See full PDF

Close


Topical agents or dressings for pain in venous leg ulcers

Read more

The Cochrane Collaboration

Venous leg ulcers affect up to 1% of people at some time in their lives and are often painful. The main treatments are compression bandages and dressings. Topical treatments to reduce pain during and between dressing changes are sometimes used.

See full PDF

Close


Pain at wound dressing-related procedures: a template for assessment

Read more

World Wide Wounds

This paper presents a simple, practical framework to assess a patients experience of pain at wound dressing-related procedures that has been inspired by the World Union of Wound Healing Societies’ consensus document.

See full PDF

Close


Pain and stress as contributors to delayed wound healing

Read more

Upton D & Solowiej K

It is possible that patients who suffer from acute and chronic wounds can interpret wound pain as a stressor. It is known from previous research that stress can delay wound healing; however, little is known about the influence of pain in this relationship. This review explores the literature surrounding the relationship between stress, pain and delayed healing of acute and chronic wounds. Many studies have demonstrated the impact of stress on the healing of biopsy, surgical and chronic wounds and there is a range of medical, psychological and social interventions that may reduce both pain and stress and consequently speed up wound healing.

See full PDF

Close


Pain and wound healing in surgical patients

Read more

Annals of Behavioral Medicine

Human and animal laboratory studies have shown that stress delays healing of standardised punch biopsy wounds. This 5-week prospective study of 17 women who underwent elective gastric bypass surgery addressed the association between postsurgical pain intensity and subsequent healing of a standard 2.0-mm punch biopsy wound.

See full PDF

Close


Pain at wound dressing changes

Read more

European Wound Management Association (EWMA)

Understanding wound pain and trauma, the theory of pain, and pain at wound dressing changes: a guide to management.

See full PDF

Close


Acute and chronic pain: where we are and where we have to go

Read more

Acute and chronic pain: where we are and where we have to go

In recent years, increasing attention has been focused on the treatment of acute and chronic pain with a considerable number of publications about it. Nevertheless all the attention focused on it, the evidence of pain treatments is still unfolding, and occasionally conflicting. Hence it is still necessary that we point out our research efforts in trying to obtain a better understand of pathophysiology of pain and of real efficacy and safety of acute and chronic pain treatments.

See full PDF

Close


Exploring the effects of pain and stress on wound healing

Read more

Clinical Management Extra

Wound-related pain is complex, involving a multitude of physiological and psychological factors, such as emotional state, culture, personality, meanings, and expectations. The impact of pain on the individual can contribute to stress and compromise quality of life. The purpose of this article is to review the relationships among pain, stress, and wound healing.

See full PDF

Close


Wound bed preparations

Wound bed preparation is a comprehensive approach to wound management that focuses on optimising conditions at the wound bed to encourage normal endogenous processes of healing. It is based on an understanding of the underlying molecular processes of the wound and is in a continuous state of evolution as it incorporates and responds to new information about and understanding of cellular mechanisms. The following scientific publications and reference materials explain the concept of TIME wound healing about the relevance of wound bed preparation to diabetic wounds and burns:

What have we learned in the past 10 years?

Read more

Extending the TIME concept

The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention. However, it should be recognised that the TIME principles are only a part of the systematic and holistic evaluation of each patient at every wound assessment. This review, prepared by the International Wound Infection Institute, examines how new data and evidence generated in the intervening decade affects the original concepts of TIME, and how it is translated into current best practice.

See full PDF

Close


Wound bed preparation in practice

Read more

European Wound Management Association (EWMA)

The last two decades have focused on improving the healing rates of patients with a wide range of chronic wounds. It is now realistic to expect that, with evidence-based care, many wounds will heal uneventfully within a reasonable timeframe. Despite overall improvements, however, there remains a small but significant proportion of chronic wounds that fail to heal even with the highest standard of care. The management of these wounds has therefore come under scrutiny and attention has turned to the factors that influence their healing and to the preparation of the wound bed.

See full PDF

Close


New concepts and scientific applications

Read more

Wound healing and TIME

This article reviews recent thinking about the relevance of wound bed preparation to diabetic wounds and burns, presents adjustments to the tissue, infection/ inflammation, moisture imbalance, epidermis/edge (TIME) paradigm of wound management to reflect greater understanding concerning migration of the epidermal edge, and provides an extension of the concept to include wound assessment. Finally, it asks whether TIME should now be put to the test. The field of wound management is lacking in robust data, but now that a more systematic approach to wound care exists, perhaps a more systematic approach to gathering the evidence should also be attempted.

See full PDF

Close


Future opportunities

Future near term opportunities for Medi-Solfen®, include the treatment of traumatic wounds caused by surgical procedures, and mass trauma situations such as accidents, military conflict and natural disasters.

Future human indications include:

  • Chronic wound care
    • Diabetic leg ulcers
  • Immediate wound treatment
    • Medical clinics
    • Defence forces
    • Emergency services
    • Natural disaster situations
  • Post-surgery wound care
    • Post-surgical treatments
  • Over-the-counter first aid treatments